U.S. Markets closed

Acorda to Present Data at the International Congress of Parkinson’s Disease and Movement Disorders

ARDSLEY, N.Y.--(BUSINESS WIRE)--

Acorda Therapeutics, Inc. (ACOR) today announced that it will present data at the International Congress of Parkinson’s Disease and Movement Disorders, taking place September 22-26, 2019 in Nice, France.

The data include two posters, which will be presented on Tuesday, September 24, 2019 from 1:45 PM to 3:15 PM CEST:

  • Dyskinesia Rates in Patients with Parkinson’s Disease on CVT-301 (levodopa inhalation powder)(Abstract #1035)
  • Impact of OFF periods on aspects of employment for people with Parkinson’s disease(Abstract #905)

Acorda and other industry sponsors are members of The Michael J. Fox Foundation Industry Advisory Board and contributed to the design of and provided funding for the “Financial and Social Impact of Parkinson’s Disease Survey.” Results of the survey were also presented at the 5th World Parkinson Congress in June 2019.

Acorda will also host a Corporate Therapeutics Symposium, “Rethinking the Approach to Managing OFF Periods,” on Tuesday, September 24 from 12:45 PM to 1:45 PM CEST in the Nice Acropolis Convention Centre. The symposium will be led by Peter LeWitt, M.D., M.Med.Sc., Director of the Parkinson’s Disease and Movement Disorders Program at Henry Ford Hospital, Fernando Pagan, M.D., Professor and Vice Chairman for the Department of Neurology at MedStar Georgetown University Hospital, and Mark Lew, M.D., Professor of Clinical Neurology at the Keck School of Medicine of the University of Southern California.

About Acorda Therapeutics

Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders. INBRIJA™ (levodopa inhalation powder) is approved for intermittent treatment of OFF episodes in adults with Parkinson’s disease treated with carbidopa/levodopa. INBRIJA is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor such as phenelzine or tranylcypromine within the last two weeks. INBRIJA utilizes Acorda’s innovative ARCUS® pulmonary delivery system, a technology platform designed to deliver medication through inhalation. Acorda also markets the branded AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg.

Forward-Looking Statement

This press release includes forward-looking statements. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including: we may not be able to successfully market Inbrija or any other products under development; risks associated with complex, regulated manufacturing processes for pharmaceuticals, which could affect whether we have sufficient commercial supply of Inbrija to meet market demand; third party payers (including governmental agencies) may not reimburse for the use of Inbrija or our other products at acceptable rates or at all and may impose restrictive prior authorization requirements that limit or block prescriptions; competition for Inbrija, Ampyra and other products we may develop and market in the future, including increasing competition and accompanying loss of revenues in the U.S. from generic versions of Ampyra (dalfampridine) following our loss of patent exclusivity; the ability to realize the benefits anticipated from acquisitions, among other reasons because acquired development programs are generally subject to all the risks inherent in the drug development process and our knowledge of the risks specifically relevant to acquired programs generally improves over time; we may need to raise additional funds to finance our operations and may not be able to do so on acceptable terms; the risk of unfavorable results from future studies of Inbrija (levodopa inhalation powder) or from our other research and development programs, or any other acquired or in-licensed programs; the occurrence of adverse safety events with our products; the outcome (by judgment or settlement) and costs of legal, administrative or regulatory proceedings, investigations or inspections, including, without limitation, collective, representative or class action litigation; failure to protect our intellectual property, to defend against the intellectual property claims of others or to obtain third party intellectual property licenses needed for the commercialization of our products; and failure to comply with regulatory requirements could result in adverse action by regulatory agencies.

These and other risks are described in greater detail in our filings with the Securities and Exchange Commission. We may not actually achieve the goals or plans described in our forward-looking statements, and investors should not place undue reliance on these statements. Forward-looking statements made in this press release are made only as of the date hereof, and we disclaim any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190918005090/en/